Once-daily combination therapy with emtricitabine, didanosine, and efavirenz in human immunodeficiency virus-infected patients

Journal of Infectious Diseases

Volumn 182, Issue 2, 2000, Pages 599-602

  Molina, Jean Michel ^a   Ferchal, Françoise ^a   Rancinan, Corinne ^c   Raffi, François ^e   Rozenbaum, Willy ^b   Sereni, Daniel ^a   Morlat, Philippe ^d   Journot, Valérie ^c   Decazes, Jean Marie ^a   Chêne, Geneviève ^c  

^a SAINT LOUIS HOSPITAL   (France)

^b HÔPITAL ROTHSCHILD   (France)

^c INSERM   (France)

^d HÔPITAL SAINT ANDRÉ   (France)

^e HÔTEL DIEU   (France)

Author keywords

[No Author keywords available]

Indexed keywords

DIDANOSINE; EFAVIRENZ; EMTRICITABINE;

ABDOMINAL PAIN; ADULT; AFFECTIVE NEUROSIS; ARTICLE; DEPRESSION; DIARRHEA; DRUG EFFICACY; DRUG MIXTURE; DRUG SAFETY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERAMYLASEMIA; HYPERTRIGLYCERIDEMIA; INSOMNIA; MAJOR CLINICAL STUDY; MALE; NEUTROPENIA; PRIORITY JOURNAL; RASH; SLEEP DISORDER; VIRUS LOAD;

ADULT; ANTI-HIV AGENTS; CD4 LYMPHOCYTE COUNT; DEOXYCYTIDINE; DIDANOSINE; DRUG THERAPY, COMBINATION; HIV INFECTIONS; HIV-1; HUMANS; MALE; OXAZINES; PILOT PROJECTS; RNA, VIRAL;

EID: 0033847883     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/315711     Document Type: Article

References (14)

1. Antiretroviral therapy in adults: Updated recommendations of the International AIDS Society - USA panel
2. Improved survival among HIV-infected individuals following initiation of antiretroviral therapy
3. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less
4. The value of patient-reported adherence to antiretroviral therapy in predicting virologic and immunologic response
5. Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: A cohort study
6. Efavirenz
7. Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults
8. Virological and immunologic responses to once-daily dosing of didanosine in combination with stavudine
9. Comparison of the plasma pharmacokinetic and renal clearance of didanosine during once and twice daily dosing in HIV-infected individuals
10. Selective inhibition of human immunodeficiency viruses by racemates and enantiomers of cis-5-fluoro-1-(2-(hydroxymethyl)1,3-oxathiolan-5-yl)cytosine
11. Selection of FTC dose based on viral kinetics and pharmacokinetics in an accelerated clinical trial design
12. A phase I/II randomized controlled study of FTC versus 3TC in HIV infected patients
13. Potent antiretroviral efficacy of low dose FTC: Initial results from a phase I/II clinical trial
14. The duration of viral suppression during protease inhibitor therapy for HIV-1 infection is predicted by plasma HIV RNA at the nadir